Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Mortality (b) 28% Zhao et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? Retrospective 2,070 patients in the USA Lower mortality with aspirin (p=0.00065) Zhao et al., Anesthesiology, doi:10.1097/ALN.0000000000003999 Favors aspirin Favors control
Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study
Zhao et al., Anesthesiology, doi:10.1097/ALN.0000000000003999
Zhao et al., Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort.., Anesthesiology, doi:10.1097/ALN.0000000000003999
Oct 2021   Source   PDF  
  All Studies   Meta
Retrospective 2,070 hospitalized patients in the USA, showing lower mortality with aspirin treatment.
risk of death, 43.0% lower, HR 0.57, p < 0.001, treatment 121 of 473 (25.6%), control 140 of 473 (29.6%), adjusted per study, PSM.
risk of death, 28.0% lower, HR 0.72, p = 0.03, treatment 473, control 1,597, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhao et al., 1 Oct 2021, retrospective, USA, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Critical Care Medicine ABSTRACT Background: Mortality in critically ill COVID-19 patients remains high. Although randomized controlled trials must continue to definitively evaluate treatments, further hypothesis-generating efforts to identify candidate treatments are required. This study’s hypothesis was that certain treatments are associated with lower COVID-19 mortality. Methods: This was a 1-yr retrospective cohort study involving all COVID-19 patients admitted to intensive care units in six hospitals affiliated with Yale New Haven Health System from February 13, 2020, to March 4, 2021. The exposures were any COVID-19–related pharmacologic and organ support treatments. The outcome was in-hospital mortality. Results: This study analyzed 2,070 patients after excluding 23 patients who died within 24 h after intensive care unit admission and 3 patients who remained hospitalized on the last day of data censoring. The in-hospital mortality was 29% (593 of 2,070). Of 23 treatments analyzed, apixaban (hazard ratio, 0.42; 95% CI, 0.363 to 0.48; corrected CI, 0.336 to 0.52) and aspirin (hazard ratio, 0.72; 95% CI, 0.60 to 0.87; corrected CI, 0.54 to 0.96) were associated with lower mortality based on the multivariable analysis with multiple testing correction. Propensity score–matching analysis showed an association between apixaban treatment and lower mortality (with vs. without apixaban, 27% [96 of 360] vs. 37% [133 of 360]; hazard ratio, 0.48; 95% CI, 0.337 to 0.69) and an association between aspirin treatment and lower mortality (with vs. without aspirin, 26% [121 of 473] vs. 30% [140 of 473]; hazard ratio, 0.57; 95% CI, 0.41 to 0.78). Enoxaparin showed similar associations based on the multivariable analysis (hazard ratio, 0.82; 95% CI, 0.69 to 0.97; corrected CI, 0.61 to 1.05) and propensity score–matching analysis (with vs. without enoxaparin, 25% [87 of 347] vs. 34% [117 of 347]; hazard ratio, 0.53; 95% CI, 0.367 to 0.77). Xu Zhao, M.D., Chan Gao, M.D., Ph.D., Feng Dai, Ph.D., Miriam M. Treggiari, M.D., Ph.D., M.P.H., Ranjit Deshpande, M.D., F.C.C.M., Lingzhong Meng, M.D. Anesthesiology 2021; 135:1076–90 EDITOR’S PERSPECTIVE What We Already Know about This Topic • While the treatment of critically ill COVID-19 patients has improved, mortality rates remain high What This Article Tells Us That Is New • In a retrospective cohort consisting of 2,070 critically ill COVID-19 patients treated in six hospitals, multivariable regression analysis showed lower in-hospital mortality associated with apixaban, aspirin, or enoxaparin treatment • Propensity score–matching analyses demonstrated lower mortality for patients receiving apixaban (27% [96 of 360] vs. 37% [133 of 360]), aspirin (26% [121 of 473] vs. 30% [140 of 473]), or enoxaparin (25% [87 of 347) vs. 34% [117 of 347]) compared to matched controls A Particular challenge of COVID-19 treatment is the high mortality, especially among critically ill patients. Although the mortality rate was estimated to be ~50% among critically ill COVID-19 patients in the early stage of the pandemic,1 a study performed at a later stage of the pandemic showed a downward trend of mortality rates from ~44% to ~19%.2 Effective treatments might be one factor responsible for this decline. Continuous efforts in Conclusions: Consistent with the known hypercoagulability in severe COVID-19, the use of apixaban, enoxaparin, or aspirin was independently associated with lower mortality in critically ill COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop